Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15-25 years old healthy Korean women

OBJECTIVE: The study assessed the immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Korean women aged 15-25 years. METHODS: Phase IIIB, double-blind, randomised (2:1), multi-centre trial was conducted in Korea from June 2007 to March 200...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seung Cheol, Song, Yong Sang, Kim, Young-Tae, Kim, Young Tak, Ryu, Ki-Sung, Gunapalaiah, Bhavyashree, Bi, Dan, Bock, Hans L, Park, Jong-Sup
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Gynecologic Oncology and Colposcopy 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152758/
https://www.ncbi.nlm.nih.gov/pubmed/21860731
http://dx.doi.org/10.3802/jgo.2011.22.2.67

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152758/
https://www.ncbi.nlm.nih.gov/pubmed/21860731
http://dx.doi.org/10.3802/jgo.2011.22.2.67

Ejemplares similares